Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2022 | ASC2ESCALATE: dose escalation study of asciminib in second-line CP-CML

Jorge Cortes • 29 Sep 2022

SOHO 2022

Chronic Myeloid Leukemia Leukemia Asciminib

ASC2ESCALATE

Jorge Cortes, MD, Augusta University, Augusta, GA, explains the rationale for the ASC2ESCALATE trial (NCT05384587), which aims to determine whether it is possible to escalate the dosing of asciminib from 80 mg to 200 mg twice daily in patients with chronic myeloid leukemia in the chronic phase (CP-CML) who have not achieved their goal of response at the 12 months. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Key emerging trials in CML and the importance of improving treatment-free remission rates

Jorge Cortes • 7 Sep 2023

Social determinants of health & their impact on patients with hematological malignancies

Jorge Cortes • 7 Sep 2023

Post-hoc analysis of OPTIC: patient responses to ponatinib by T315I mutational status

Jorge Cortes • 7 Sep 2023

Exciting updates in the field of CML: disease pathophysiology & novel agents

Jorge Cortes • 7 Sep 2023

Related Videos

Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens

Christina Peters • 15 Apr 2024

Promising novel agents in AML: menin inhibitors

Mark Levis • 16 Apr 2024

EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation

Valentin Ortiz-Maldonado • 16 Apr 2024

Do all patients require maintenance therapy following alloSCT?

Mark Levis • 16 Apr 2024